Clinical Trial Update: A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating a gemcitabine and capecitabine combination in treatment-resistant metastatic colorectal cancer; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Xeloda (capecitabine)

Snippet

Sponsor: Vejle Hospital | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED